Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Horizon Pharma"
Count: 78
Selected: 0
NCT01466166Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout
NCT03298867Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
NCT03461211Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
NCT04040894Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
NCT01733316Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis
NCT01197378Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
NCT02473445A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
NCT01868997Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
NCT01744782Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis
NCT01270347Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
NCT01180634MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis
NCT00840333"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"
NCT00752414A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00739648A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00677365Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
NCT00503490Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis
NCT02023866Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease
NCT00661141Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism
NCT01000961Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
NCT00872729Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
NCT05626751An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
NCT00986895A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
NCT00977600A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)
NCT02593773Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
NCT02797080Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
NCT02415127Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
NCT01544114A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
NCT02287610A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis
NCT01347073Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
NCT01135680Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100
NCT00999167A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
NCT00992459Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders
NCT00947544Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
NCT00947297Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
NCT00551200Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
NCT00597909Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
NCT01563185Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
NCT00984815Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
NCT00650078Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis
NCT00613106Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)
NCT00450658Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers
NCT00450216Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment
NCT00686335A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma
NCT03162341Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit
NCT04628338IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
NCT02927158Exome and Genome Analysis to Elucidate Genetic Etiologies and Population Characteristics in the Plain Community
NCT03112590Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
NCT04125459Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout
NCT02584608Use of ACTIMMUNE in Patients With ADO2
NCT02614456Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors